## PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: GEOFFREY L. MELNICK G. E. EHRLICH (1995) LTD.	PCT				
11 MENACHEM BEGIN STREET GAMAT-GAN, ISRAEL 52 521  0   FEB 20	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION (PCT Rule 44.1)				
FILE NO. OTT	Dutes Pring				
Applicant's or agent's file reference	(day/month/year) 12 JAN 2005				
27510	FOR FURTHER ACTION See paragraphs 1 and 4 below				
International application No. PCT/IL04/00643	International filing date (day/month/year) 15 July 2004 (15.07.2004)				
Applicant GAMIDA-CELL LTD.					
The applicant is hereby notified that the international sear Authority have been established and are transmitted here.	rch report and the written opinion of the International Searching with.				
Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the cl	aims of the international application (see Rule 46):				
	normally two months from the date of transmittal of the international				
Where? Directly to the International Bureau of WIPO 1211 Geneva 20, Switzerland, Facsimile No	0, 34 chemin des Colombettes : +41 22 740 14 35				
For more detailed instructions, see the notes on the a	** • • • • • • • • • • • • • • • • • •				
2. The applicant is hereby notified that no international search					
	ional fee(s) under Rule 40.2, the applicant is notified that:				
	en transmitted to the International Bureau together with the applicant's				
	plicant will be notified as soon as a decision is made.				
4. Reminders					
Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.					
The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.					
Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.					
In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.					
See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.					
Name and mailing address of the ISA/ US	Authorized officer				
Mail Stop PCT, Attn: ISA/US Commissioner for Patents	Q. Janice Li				
P.O. Box 1450 Alexandria, Virginia 22313-1450	Paralegal Sportages				
Facsimile No. (703) 305-3230	Telephone No. 703-308-0196				

Form PCT/ISA/220 (January 2004)

(See notes on accompanying sheet)

## PATENT COOPERATION TREATY

# **PCT**

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file ref	FOR FURTHER ACTION	577 T 5111 T 511 (512 22 5				
International application No. PCT/IL04/00643	International filing date (d 15 July 2004 (15.07.2004)		arliest) Priority Date (day/month/year) July 2003 (17.07.2003)			
Applicant GAMIDA-CELL LTD.						
This international search rep  It is also  Basis of the Report	accompanied by a copy of each prior as	tional Bureau.	is report.			
The	language in which it was filed, unless otherwise indicated under this item.  The international search was carried out on the basis of a translation of the international application					
	any nucleotide and/or amino acid sequ		ternational application, see Box No. I.			
	were found unsearchable (See Box No.	. II)				
4. With regard to the title	<ol> <li>Unity of invention is lacking (See Box No. III)</li> <li>With regard to the title,</li> </ol>					
the text is appro	the text is approved as submitted by the applicant.					
the text has been established by this Authority to read as follows:						
5. With regard to the abst	· ·					
	ved as submitted by the applicant.					
may, within one	n established, according to Rule 38.2(b), month from the date of mailing of this i	by this Authority as it a nternational search repo	appears in Box No. IV. The applicant ort, submit comments to this Authority.			
<ul><li>6. With regard to the drawings,</li><li>a. the figure of the drawings to be published with the abstract is Figure No</li></ul>						
	ested by the applicant.					
as selec	ted by this Authority, because the applicated	ant failed to suggest a fi	gure.			
1 1	ted by this Authority, because this figure					
b. none of the figu	res is to be published with the abstract.					
form PCT/ISA/210 (first sheet)	(January 2004)					

Form PCT/ISA/210 (first sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL04/00643

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12N 5/00, 02					
US CL According to	: 435/325, 375, 377 International Patent Classification (IPC) or to both na	itional class	ification and IDC		
	DS SEARCHED	tional crass	incation and if C		
	Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/325, 375, 377				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic da	ta base consulted during the international search (nam	e of data ba	se and, where practicable, sear	ch terms used)	
	UMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where a	ppropriate,	of the relevant passages	Relevant to claim No.	
A	EHRING, B. ET AL, Expansion of HPCs from con	d blood in a	novel 3D matrix.	1-50	
A	Cytotherapy 2003, Vol. 5 (6), pages 490-499.  RYU, J.K. ET AL, Adenosine triphosphate induces proliferation of human neural stem cells: Role of calcium and p70 ribosomal protein S6 kinase. J NEUROSCI RES. 2003  MAY, VOL. 72:352-362.			1-50	
A	A MATUOKA, K. ET AL, A positive role of phosphatidylinositol 3-kinase in aging phenotype expression in cultured human diploid fibroblasts. ARCH GERONTOL GERIATR 2003, VOL. 36, pages 203-219.			1-50	
Further	documents are listed in the continuation of Box C.		See patent family annex.		
"A" document	pecial categories of cited documents:  defining the general state of the art which is not considered to be lar relevance	"T"	later document published after the inter date and not in conflict with the applica principle of theory underlying the inver- document of particular relevance; the c	ition but cited to understand the	
"E" earlier app	plication or patent published on or after the international filing date		considered novel or cannot be consider		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to document of particular relevance; the considered to involve an inventive step combined with one or more other such			when the document is .		
"O" document referring to an oral disclosure, use, exhibition or other means combined with one or more other such documents, such combination being obvious to a person skilled in the art					
"P" document published prior to the international filing date but later than the "&" document member of the same patent family priority date claimed					
Date of the actual completion of the international search  Date of mailing of the international search report  12 JAN 2005					
Name and mailing address of the ISA/US Authorized officer					
	Mail Stop PCT, Attn: ISA/US Commissioner for Patents  Q. Janice Li  Jean Pro-				
P.O. Alex	P.O. Box 1450 Alexandria, Virginia 22313-1450  Telephone No. 703-308-0196				
	Facsimile No. (703) 305-3230				

Form PCT/ISA/210 (second sheet) (January 2004)

## PATENT COOPERATION TREATY

j	From the					
	INTERNATIONAL SEARCHING AUTHORITY  To: GEOFFREY L. MELNICK G. E. EHRLICH (1995) LTD. 11 MENACHEM BEGIN STREET GAMAT-GAN, ISRAEL 52 521		PCT  WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY			
			11/12/1/1/1	(PCT Rule 43bis, 1)		
			Date of mailing			
	Applicant's on apply 51, action		(day/month/year) 12 JAN 2000			
	Applicant's or agent's file reference		FOR FURTHER ACTION See paragraph 2 below			
	27510 International application No.	International filing date				
				Priority date (day/month/year)		
	PCT/IL04/00643 International Patent Classification (IPC) o	15 July 2004 (15.07.200 or both national classifica	04) tion and IPC	17 July 2003 (17.07.2003)		
	IPC(7): C12N 5/00, 02 and US C1.: 435/					
	Applicant 4337.	323, 373, 377	· · · · · · · · · · · · · · · · · · ·			
	GAMIDA-CELL LTD.					
	This opinion contains indications rela	ating to the following iten	ns:			
	Box No. I Basis of the opinion					
	Box No. II Priority					
	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			entive step and industrial applicability		
	Box No. IV Lack of unity of invention			with over the industrial approximity		
	Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			o novelty, inventive step or industrial		
	Box No. VI Certain documents cited					
Box No. VII Certain defects in the international application						
Box No. VIII Certain observations on the international application						
	2. FURTHER ACTION					
	If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.					
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.						
For further options, see Form PCT/ISA/220.						
	3. For further details, see notes to Form PCT/ISA/220.					
ļ	Name and mailing address of the ISA/ US		Authorized officer			
	Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Q. Janice Li	🕥		
	P.O. Box 1450		`	Parate you So		
	Alexandria, Virginia 22313-1450		Telephone No. 70	- "		
Ļ	Facsimile No. (703) 305-3230 Form PCT/ISA/237 (cover sheet) (January 2	2004)	1			
-	Carabianas (corei affect) (January	200T)				

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

	INTERNATIONAL SEARCHING AUTHORITY	PCT/IL04/00643		
Box N	o. I Basis of this opinion			
I. With	regard to the language, this opinion has been established on the basis of t	the international application in the learning in the learning		
it was	filed, unless otherwise indicated under this item.	me memational application in the language in which		
	This opinion has been established on the basis of a translation from the ownich is the language of a translation furnished for the purposes of inter-	original language into the following language, national search (under Rules 12.3 and 23.1(b)).		
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:				
a.	type of material			
	a sequence listing			
	table(s) related to the sequence listing			
b.	format of material			
	in written format			
	in computer readable form			
c.	time of filing/furnishing			
	contained in international application as filed.			
	filed together with the international application in computer reada	ble form.		
	furnished subsequently to this Authority for the purposes of search	1.		
3. 🗌	In addition, in the case that more than one version or copy of a seque filed or furnished, the required statements that the information in the suf the application as filed or does not go beyond the application as filed, as	bsequent or additional conies is identical to that in		
4. Additi	onal comments:			

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

Form PCT/ISA/237 (Box No. V) (January 2004)

International application No. PCT/IL04/00643

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
1. Statement			
Novelty (N)	Claims	1-50	YES
	Claims		NO
Inventive step (IS)	Claims	1.50	YES
	Claims		NO NO
Industrial applicability (IA)	Claims	1.50	MEG
moust far applications (123)	Claims		YES NO
Claims 1-50 meet the criteria set out in PCT Article inhibitors such as wortmannin or LY294002 could be Claims 1-50 meet the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article could be contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the criteria set out in PCT Article contained as the	be used for expan	inding stem and progenitor cell	ls in a bioreactor.
can be made or used in industry.			

#### NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

## The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- 1. [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- 2. [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
   "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
  - "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

#### "Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

#### It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

### Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide, Volume II.